Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

A $30 Million Reason to Buy Penny Stock Longeveron Today

Longeveron (LGVN) stock closed significantly higher on March 10 after the biotech firm announced a private placement generating about $30 million from institutional and accredited investors. 

The financing comprises an initial $15 million tranche with potential for an additional $15 million contingent upon achieving specific milestones related to the anticipated Phase 2b ELPIS II clinical trial.

Fundamentals

See More
  • Market Capitalization, $K 19,008
  • Shares Outstanding, K 21,333
  • Annual Sales, $ 2,390 K
  • Annual Income, $ -15,970 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.23
  • Price/Sales 8.95
  • Price/Cash Flow N/A
  • Price/Book 1.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.06
  • Most Recent Earnings $-0.39 on 11/04/25
  • Next Earnings Date 03/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.41
  • Low Estimate -0.42
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4750 +71.05%
on 03/06/26
1.1700 -30.56%
on 03/10/26
+0.2713 (+50.13%)
since 02/11/26
3-Month
0.4750 +71.05%
on 03/06/26
1.1700 -30.56%
on 03/10/26
+0.1855 (+29.59%)
since 12/11/25
52-Week
0.4750 +71.05%
on 03/06/26
1.9198 -57.68%
on 03/24/25
-0.7375 (-47.58%)
since 03/11/25

Most Recent Stories

More News
Longeveron Announces Closing of Private Placement of up to $30 Million

$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)
A $30 Million Reason to Buy Penny Stock Longeveron Today

Longeveron shares rip higher as the biotech firm raises $30 million via a private placement. Here’s why it may not be too late to invest in LGVN stock yet.

LGVN : 0.8125 (-8.81%)
Longeveron Announces Private Placement of up to $30 Million

$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

The  Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029 The...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs,...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

ELPIS II top-line trial results are anticipated in the third quarter of 2026 Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditions Supported by Health Moonshot Champions, including the Alzheimer’s...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual...

LGVN : 0.8125 (-8.81%)
LGVNR : 0.0005 (-37.50%)

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 0.9895
2nd Resistance Point 0.9392
1st Resistance Point 0.8758
Last Price 0.8125
1st Support Level 0.7621
2nd Support Level 0.7118
3rd Support Level 0.6484

See More

52-Week High 1.9198
Fibonacci 61.8% 1.3679
Fibonacci 50% 1.1974
Fibonacci 38.2% 1.0269
Last Price 0.8125
52-Week Low 0.4750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar